Skip to content
Nextera AS logo

Nextera AS Alternatives & Competitors

12 companies similar to Nextera AS — Opening a new arena for drug discovery

Companies similar to Nextera AS

Tridek-One logo — alternative to Nextera AS

Tridek-One

We develop first-in-class CD31 checkpoint agonists for the treatment of auto-immune diseas...

Cullgen Inc. logo — alternative to Nextera AS

Cullgen Inc.

Powering protein degradation for tomorrow's medicines

OSE Immunotherapeutics logo — alternative to Nextera AS

OSE Immunotherapeutics

Immuno-Oncology and Immuno-Inflammation - Breakthrough Immuno-Science for Patients

Laminar Pharma logo — alternative to Nextera AS

Laminar Pharma

Biopharmaceutical company performing discovery, rational design and initial clinical devel...

Rival Readout

Competing with Nextera AS? We do this properly.

10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.

Book a 7-day Readout
Evommune logo — alternative to Nextera AS

Evommune

Developing innovative therapies that target key drivers of chronic inflammatory diseases.

Kangpu Biopharmaceuticals, Ltd. logo — alternative to Nextera AS
Sentien Biotechnologies, Inc. logo — alternative to Nextera AS

Sentien Biotechnologies, Inc.

Restoring Balance to the Immune System

Synta Pharmaceuticals logo — alternative to Nextera AS

Synta Pharmaceuticals

Innovating patient care with advanced small molecule therapies for severe medical conditio...

Eugit Therapeutics logo — alternative to Nextera AS

Eugit Therapeutics

Tissue targeting of therapies

Chance Pharmaceuticals 畅溪制药 logo — alternative to Nextera AS

Chance Pharmaceuticals 畅溪制药

A clinical-stage biotech company focusing on discovering, developing and commercializing i...

Attovia Therapeutics logo — alternative to Nextera AS

Attovia Therapeutics

Creating medicines for immune-mediated disease using ATTOBODY®, a proprietary biologics pl...

InflaRx logo — alternative to Nextera AS

InflaRx

Controlling Inflammation - developing drugs to treat life threatening and chronic inflamma...

About Nextera AS

Nextera AS is a biotechnology startup based in Norway founded in 2009. The company's slogan, "Opening a new arena for drug discovery," reflects its mission to revolutionize therapeutic intervention in autoimmunity, chronic inflammatory disorders, and cancer. Nextera's distinctive approach involves modulating diseases a...

Business keywords

Drug Discovery, Therapeutic Intervention, Autoimmunity, Chronic Inflammatory Disorders, Cancer Treatment, Target Discovery, New Targets, Cognate Drugs, Complex Diseases, Therapies Development, Immune System Modulation, Clinical Material Analysis, Diseased Tissue Focus, Immune Cascade, Patient-centered Approach

Frequently Asked Questions

Companies similar to Nextera AS include Tridek-One, Cullgen Inc., OSE Immunotherapeutics, Laminar Pharma, Evommune. They work in Biotechnology and Health Care and share Nextera AS's focus on drug discovery, cancer treatment and immune system modulation.
Bounce Watch lists 12 companies that share Nextera AS's industries and are closest to it in business tags, services, target customers, business model and size.
Nextera AS is a biotechnology startup based in Norway founded in 2009. The company's slogan, "Opening a new arena for drug discovery," reflects its mission to revolutionize therapeutic intervention in autoimmunity, chronic inflammatory disorders, and cancer. Nextera's distinctive approach involves modulating diseases a...

From the desk

Mapping a market? Start with a Rival Readout.

In 7 business days we read 10 rivals around Nextera AS: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.

Compiled from the BounceWatch company index. We last looked at Nextera AS on 12 Sep 2024. The 12 companies listed here were last checked between 11 Sep 2024 and 9 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout